Trump Executive Order Tracker | Akin Public Policy and Lobbying

Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve (Trump EO Tracker)

August 13, 2025

Reading Time : 2 min
Trump Executive Order Tracker | Akin Public Policy and Lobbying

The Executive Order aims to bolster the resilience of the United States’s pharmaceutical supply chain by stockpiling Active Pharmaceutical Ingredients (“APIs”) for critical medicines in the Strategic Active Pharmaceutical Ingredients Reserve (“SAPIR”) and encouraging the domestic production and procurement of such APIs.

The EO includes several directives and deadlines.

  • Section 2(a): Within 30 days of the EO, the Office of the Assistant Secretary for Preparedness and Response (“ASPR”) within the Department of Health and Human Services must create a list “of approximately 26 drugs that are especially critical to the health and security interests of the Nation (the critical drugs).” The ASPR must also create an accounting of funds available to finance and maintain the SAPIR repository with a 6-month supply of APIs for critical drugs referenced in Section 2(c). The list and accounting must be provided to the Director of the Office of Management and Budget (“OMB”), who will assist with repurposing available funds.
  • Section 2(b): Within 120 days of the EO, and subject to the availability of funds identified in Section 2(a), the ASPR must prepare the existing SAPIR repository to begin receiving and maintaining APIs.
  • Section 2(c): Subject to the availability of funds identified in Section 2(a), the ASPR must secure a 6-month supply of APIs needed to make critical drugs, prioritizing APIs manufactured domestically. APIs must be placed within the SAPIR repository within 30 days after the repository is certified to receive and maintain APIs.
  • Section 3(a): Within 90 days of the EO, the ASPR must update its 2022 list of 86 essential medicines and medical countermeasures and provide it to the Assistant to the President and Homeland Security Advisor (“APHSA”), the Assistant to the President for Economic Policy (“APEP”), and OMB. The update should include a plan to obtain APIs for drugs on the updated essential medicines list from domestic manufacturers, where possible, and to store and maintain a 6-month supply of those APIs.
  • Section 3(b): The plan in Section 3(a) must also include a proposal to open a second SAPIR site within one year of the EO.

Additional Documentation

Share This Insight

Related Content

Trump Executive Order Tracker

The significant number of executive orders published by the Trump Administration cut across dozens of industries and areas of law. This searchable tool breaks down the orders and their impacts on specific industries and with in-depth analysis of specific orders.

Previous Entries

Trump Executive Order Tracker

December 19, 2025

Sets a strategy for U.S. leadership in 6G technology, emphasizing its importance for national security, AI, robotics, and resilient communications. It directs the Commerce Department’s National Telecommunications and Information Administration to “immediately begin the process of identifying” the 7.125-7.4 GHz band for “reallocation for full-powered commercial licensed use” and study how to reallocate federal systems in the band “to other frequencies” while ensuring that critical defense and electric grid missions remain unaffected. Authorizes studies to explore reallocating portions of the 2.69–2.9 GHz and 4.4–4.94 GHz bands. These efforts aim to accelerate spectrum availability for next-generation networks without compromising existing federal operations. Tasks the State Department and other agencies to lead diplomatic efforts with the ITU to advance U.S. objectives on global spectrum policy.

...

Read More

Trump Executive Order Tracker

December 18, 2025

This order directs the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act. Schedule III drugs are classified as having a potential for abuse less than those drugs in Schedules I and II, a currently accepted medical use in treatment in the United States, and a potential for moderate or low physical dependence or high psychological dependence in the event of drug abuse.

...

Read More

Trump Executive Order Tracker

December 16, 2025

Suspends entry for foreign nationals of additional countries of concern from those previously restricted under Proclamation 10949, as determined by the Secretary of State, the Secretary of Homeland Security, the Attorney General, and the Director of National Intelligence. Additional countries include full suspension of entry for Burkina Faso, Laos, Mali, Niger, Sierra Leone, South Sudan, Syria, Palestinian Authority Documents, and partial suspension of entry for Angola, Antigua and Barbuda, Benin, Cote d ‘Ivoire, Dominica, Gabon, the Gambia, Malawi, Mauritania, Nigeria, Senegal, Tanzania, Tonga, Turkmenistan, Zambia, and Zimbabwe.

...

Read More

Trump Executive Order Tracker

December 15, 2025

Designates illicit fentanyl and its core precursor chemicals as Weapons of Mass Destruction (WMD) and directs the use of national security, criminal, sanctions, intelligence, and military-support authorities to combat fentanyl trafficking. Expands enforcement tools against cartels and foreign terrorist organizations involved in fentanyl production and distributions.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.